相似文献
1
Breakthrough Candida krusei fungemia during fluconazole prophylaxis followed by breakthrough zygomycosis during caspofungin therapy in a patient with severe aplastic anemia who underwent stem cell transplantation.
J Clin Microbiol. 2005 Oct;43(10):5395-6. doi: 10.1128/JCM.43.10.5395-5396.2005.
2
Breakthrough C. parapsilosis and C. guilliermondii blood stream infections in allogeneic hematopoietic stem cell transplant recipients receiving long-term caspofungin therapy.
Haematologica. 2008 Apr;93(4):639-40. doi: 10.3324/haematol.11149.
3
Candida glabrata and Candida krusei fungemia after high-risk allogeneic marrow transplantation: no adverse effect of low-dose fluconazole prophylaxis on incidence and outcome.
Bone Marrow Transplant. 2001 Nov;28(9):873-8. doi: 10.1038/sj.bmt.1703252.
4
Caspofungin for refractory candidemia in neonates.
Pediatr Infect Dis J. 2006 Mar;25(3):282-3. doi: 10.1097/01.inf.0000200141.46957.71.
5
In vitro susceptibility of breakthrough Candida bloodstream isolates correlates with daily and cumulative doses of fluconazole.
Antimicrob Agents Chemother. 2006 Oct;50(10):3496-8. doi: 10.1128/AAC.00741-06.
6
Successful treatment of Candida krusei infection with caspofungin acetate: a new antifungal agent.
Crit Care Med. 2003 May;31(5):1577-8. doi: 10.1097/01.CCM.0000063145.15336.31.
7
Septic Candida krusei thrombophlebitis of inferior vena cava with persistent fungemia successfully treated by new antifungal agents.
Med Mycol. 2005 Dec;43(8):731-4. doi: 10.1080/13693780500302593.
8
Successful treatment of Candida krusei fungemia with amphotericin B and caspofungin.
Med Mycol. 2006 Nov;44(7):655-7. doi: 10.1080/13693780600686929.
9
Emergence of a Candida krusei isolate with reduced susceptibility to caspofungin during therapy.
Antimicrob Agents Chemother. 2006 Jul;50(7):2522-4. doi: 10.1128/AAC.00148-06.
10
Successful caspofungin treatment of multidrug resistant Candida parapsilosis septicaemia in an extremely low birth weight neonate.
Mycoses. 2006 May;49(3):242-5. doi: 10.1111/j.1439-0507.2006.01220.x.
引用本文的文献
1
Diagnosis and treatment of invasive fungal infections focus on liposomal amphotericin B.
Clin Drug Investig. 2013 Feb;33 Suppl 1:S5-14. doi: 10.1007/s40261-012-0023-3.
2
Mucormycosis in Mato Grosso, Brazil: a case reports, caused by Rhizopus microsporus var. oligosporus and Rhizopus microsporus var. rhizopodiformis.
Mycopathologia. 2012 Mar;173(2-3):187-92. doi: 10.1007/s11046-011-9472-0. Epub 2011 Sep 28.
3
Increasing incidence of zygomycosis (mucormycosis), France, 1997-2006.
Emerg Infect Dis. 2009 Sep;15(9):1395-401. doi: 10.3201/eid1509.090334.
4
Carbon assimilation profiles as a tool for identification of zygomycetes.
J Clin Microbiol. 2007 May;45(5):1433-9. doi: 10.1128/JCM.02219-06. Epub 2007 Feb 28.
本文引用的文献
1
Breakthrough fusariosis in a patient with acute lymphoblastic leukemia receiving voriconazole prophylaxis.
Clin Infect Dis. 2005 Apr 15;40(8):1212-3. doi: 10.1086/428849.
2
Breakthrough zygomycosis during empirical voriconazole therapy in febrile patients with neutropenia.
Clin Infect Dis. 2005 Mar 1;40(5):770-1. doi: 10.1086/427759.
3
Zygomycosis after prolonged use of voriconazole in immunocompromised patients with hematologic disease: attention required.
Clin Infect Dis. 2005 Feb 15;40(4):e35-7. doi: 10.1086/427752. Epub 2005 Jan 25.
4
Breakthrough zygomycosis during voriconazole treatment for invasive aspergillosis.
Haematologica. 2004 Nov;89(11):ECR42.
5
Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia.
N Engl J Med. 2004 Sep 30;351(14):1391-402. doi: 10.1056/NEJMoa040446.
6
Invasive zygomycosis in hematopoietic stem cell transplant recipients receiving voriconazole prophylaxis.
Clin Infect Dis. 2004 Aug 15;39(4):584-7. doi: 10.1086/422723. Epub 2004 Jul 30.
7
Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole.
Clin Infect Dis. 2004 Sep 1;39(5):743-6. doi: 10.1086/423274. Epub 2004 Aug 13.
8
Efficacy and feasibility of aerosolized amphotericin B lipid complex therapy in caspofungin breakthrough pulmonary zygomycosis.
Bone Marrow Transplant. 2004 Sep;34(5):467-8. doi: 10.1038/sj.bmt.1704552.
9
Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants.
N Engl J Med. 2004 Feb 26;350(9):950-2. doi: 10.1056/NEJM200402263500923.
10
Breakthrough trichosporonosis in a bone marrow transplant recipient receiving caspofungin acetate.
Clin Infect Dis. 2002 Aug 1;35(3):E35-6. doi: 10.1086/341305. Epub 2002 Jun 27.
Zotero 插件